Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
Enlivex Therapeutics (Nasdaq: ENLV) announces an exclusive live investor webinar and Q&A session scheduled for December 3, 2024, at 11:00 a.m. ET. CEO Oren Hershkovitz will discuss the company's lead product Allocetra™, its clinical status, and planned catalysts for 2025. Allocetra™ is an off-the-shelf cell therapy that reprograms macrophages to optimal functioning state, addressing conditions like osteoarthritis, sepsis, and psoriatic arthritis. Phase I/II trials have shown promising results in these multi-billion-dollar markets. Investors can pre-submit questions to ENLV@redchip.com or participate in the live Q&A.
Enlivex Therapeutics (Nasdaq: ENLV) annuncia un esclusivo webinar dal vivo per gli investitori e una sessione di domande e risposte programmata per il 3 dicembre 2024, alle 11:00 ET. Il CEO Oren Hershkovitz discuterà del principale prodotto dell'azienda, Allocetra™, del suo stato clinico e dei catalizzatori pianificati per il 2025. Allocetra™ è una terapia cellulare pronta all'uso che riprogramma i macrofagi in uno stato ottimale di funzionamento, affrontando condizioni come l'osteoartrite, la sepsi e l'artrite psoriasica. Gli studi di Fase I/II hanno mostrato risultati promettenti in questi mercati da miliardi di dollari. Gli investitori possono inviare domande in anticipo a ENLV@redchip.com o partecipare alla sessione di domande e risposte dal vivo.
Enlivex Therapeutics (Nasdaq: ENLV) anuncia un exclusivo seminario web en vivo para inversores y una sesión de preguntas y respuestas programada para el 3 de diciembre de 2024, a las 11:00 a.m. ET. El CEO Oren Hershkovitz discutirá el producto principal de la compañía, Allocetra™, su estado clínico y los catalizadores planificados para 2025. Allocetra™ es una terapia celular lista para usar que reprograma los macrófagos a un estado óptimo de funcionamiento, abordando condiciones como la osteoartritis, la sepsis y la artritis psoriásica. Los ensayos de Fase I/II han mostrado resultados prometedores en estos mercados multimillonarios. Los inversores pueden enviar preguntas anticipadas a ENLV@redchip.com o participar en la sesión de preguntas y respuestas en vivo.
Enlivex Therapeutics (Nasdaq: ENLV)는 2024년 12월 3일 오전 11시 ET에 예정된 독점 라이브 투자자 웨비나 및 질의응답 세션을 발표했습니다. CEO 오렌 허시코비츠가 회사의 주요 제품인 Allocetra™, 임상 상태 및 2025년 계획된 촉매에 대해 논의합니다. Allocetra™는 마크로파지를 최적의 기능 상태로 재프로그램하는 '오프 더 셀프' 세포 치료제로, 골관절염, 패혈증 및 건선 관절염과 같은 질환을 다룹니다. 1상/2상 시험에서 이러한 수십억 달러 규모의 시장에서 유망한 결과가 나타났습니다. 투자자들은 ENLV@redchip.com으로 사전 질문을 제출하거나 라이브 질의응답에 참여할 수 있습니다.
Enlivex Therapeutics (Nasdaq: ENLV) annonce un webinaire exclusif en direct pour les investisseurs et une session de questions-réponses prévue pour le 3 décembre 2024 à 11h00, heure de l'Est. Le PDG Oren Hershkovitz discutera du produit phare de la société, Allocetra™, de son état clinique et des catalyseurs prévus pour 2025. Allocetra™ est une thérapie cellulaire prête à l'emploi qui reprogramme les macrophages dans un état de fonctionnement optimal, traitant des conditions telles que l'arthrose, la septicémie et l'arthrite psoriasique. Les essais de Phase I/II ont montré des résultats prometteurs sur ces marchés de plusieurs milliards de dollars. Les investisseurs peuvent soumettre des questions à l'avance à ENLV@redchip.com ou participer à la session de questions-réponses en direct.
Enlivex Therapeutics (Nasdaq: ENLV) kündigt ein exklusives Live-Webinar für Investoren und eine Frage-Antwort-Runde an, die für den 3. Dezember 2024 um 11:00 Uhr ET geplant ist. CEO Oren Hershkovitz wird das Hauptprodukt des Unternehmens, Allocetra™, seinen klinischen Status und geplante Katalysatoren für 2025 besprechen. Allocetra™ ist eine sofort einsatzbereite Zelltherapie, die Makrophagen in einen optimalen Funktionszustand umprogrammiert und Erkrankungen wie Osteoarthritis, Sepsis und psoriatische Arthritis behandelt. Die Phase I/II-Studien haben vielversprechende Ergebnisse in diesen Milliarden-Dollar-Märkten gezeigt. Investoren können Fragen im Voraus an ENLV@redchip.com senden oder an der Live-Q&A-Session teilnehmen.
- Phase I/II clinical trials showing promising results for Allocetra™
- Product targeting multiple multi-billion-dollar market opportunities
- Versatile technology addressing multiple conditions (osteoarthritis, sepsis, psoriatic arthritis)
- None.
NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on December 3, 2024, at 11:00 a.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Enlivex Therapeutics Chief Executive Officer Oren Hershkovitz who will share insight into the Company's lead product, Allocetra™, insight into the clinical status, and 2025 planned catalysts.
Allocetra™ is an off-the-shelf, cell therapy technology that reprograms non-homeostatic macrophages to their optimal functioning state, addressing critical unmet needs in conditions like osteoarthritis, sepsis, and psoriatic arthritis. With Phase I/II clinical trials showing promising results and targeting multi-billion-dollar markets, Allocetra™ has the potential to redefine treatment paradigms for inflammatory and autoimmune diseases.
To register for the free webinar, please visit:
https://redchip.zoom.us/webinar/register/WN_jJyhETX6SQOSD6k3JhkfuA#/registration
A live Q&A session will follow the presentation. Questions can be pre-submitted to ENLV@redchip.com or online during the live event.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "could," "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
ENLV@redchip.com
SOURCE: Enlivex Therapeutics Ltd.
View the original press release on accesswire.com
FAQ
When is Enlivex Therapeutics (ENLV) hosting its investor webinar?
What conditions does Enlivex's Allocetra therapy target?
What stage of clinical development is Allocetra currently in?
How can investors participate in Enlivex's (ENLV) December 2024 webinar Q&A?
